• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    9/5/23 5:31:53 PM ET
    $AKAN
    $CTCX
    $EYPT
    $HLTH
    Medicinal Chemicals and Botanical Products
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $AKAN alert in real time by email

    Gainers

    • Akanda (NASDAQ:AKAN) shares increased by 13.5% to $0.63 during Tuesday's after-market session. Trading volume for this security closed at 668.1K, accounting for 276.8% of its average full-day volume over the last 100 days. The company's market cap stands at $2.4 million.
    • VolitionRX (AMEX:VNRX) shares moved upwards by 11.99% to $1.4. The company's market cap stands at $109.3 million.
    • Virpax Pharmaceuticals (NASDAQ:VRPX) shares moved upwards by 10.46% to $0.95. The market value of their outstanding shares is at $11.1 million.
    • Cue Health (NASDAQ:HLTH) stock moved upwards by 8.19% to $0.55. The market value of their outstanding shares is at $83.7 million.
    • Longeveron Inc. - Subscription Right (NASDAQ:LGVNR) shares increased by 7.49% to $0.04.
    • AIM ImmunoTech (AMEX:AIM) stock increased by 6.23% to $0.64. The company's market cap stands at $31.3 million.

    Losers

    • XBiotech (NASDAQ:XBIT) stock fell 6.7% to $4.49 during Tuesday's after-market session. The market value of their outstanding shares is at $136.6 million.
    • Carmell Therapeutics (NASDAQ:CTCX) stock declined by 5.61% to $4.04. The company's market cap stands at $93.2 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) stock fell 5.38% to $0.27. At the close, Novo Integrated Sciences's trading volume reached 20.9 million shares. This is 74.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $43.2 million.
    • EyePoint Pharmaceuticals (NASDAQ:EYPT) stock declined by 5.09% to $8.96. The market value of their outstanding shares is at $313.4 million.
    • Orgenesis (NASDAQ:ORGS) stock fell 5.08% to $0.71. The company's market cap stands at $21.6 million.
    • Yield10 Bioscience (NASDAQ:YTEN) shares decreased by 4.96% to $0.38. Today's trading volume for this security ended up closing at 243.6K shares, which is 86.0 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $4.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN
    $CTCX
    $EYPT
    $HLTH

    CompanyDatePrice TargetRatingAnalyst
    EyePoint Inc.
    $EYPT
    6/17/2025$28.00Outperform
    RBC Capital Mkts
    VolitionRX Limited
    $VNRX
    4/8/2025$2.50Buy
    H.C. Wainwright
    EyePoint Inc.
    $EYPT
    1/7/2025$33.00Buy
    Citigroup
    EyePoint Inc.
    $EYPT
    10/16/2024Sector Outperform
    Scotiabank
    EyePoint Inc.
    $EYPT
    8/28/2024$15.00Buy
    Jefferies
    Cue Health Inc.
    $HLTH
    3/14/2024Buy → Neutral
    BTIG Research
    Yield10 Bioscience Inc.
    $YTEN
    2/8/2024Buy → Hold
    Lake Street
    EyePoint Inc.
    $EYPT
    1/22/2024$35.00Overweight
    JP Morgan
    More analyst ratings

    $AKAN
    $CTCX
    $EYPT
    $HLTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

    Conference call to discuss financial and operational results scheduled forWednesday, April 1 at 8:30 a.m. U.S. Eastern TimeHENDERSON, Nev., March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the full fiscal year 2025.  Volition management will host a conference call tomorrow, April 1 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said:"We set out over fifteen years ago to help save lives and improve outcomes for millions of

    3/31/26 4:05:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

    HENDERSON, Nev., March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has secured an additional €2.0 million (approximately $2.3 million) in financing from Namur Invest ("NI") and Wallonie Entreprendre S.A. ("WE") in Belgium. Volition will use the proceeds from the financing for ongoing development of its Nu.Q® product portfolio, including taking forward its regulatory transition program for Nu.Q® NETs (from IVDD to IVDR), the continued research and development of a Lateral Flow product, specifically to enable access to its Nu.Q® NETs product in Low Income Countries and more.Mr. Nicolas Delahaye, Corporate Relations Manager, Namur

    3/31/26 8:16:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients

    Peer Reviewed Clinical Study for Nu.Q® Biomarkers Published in Shock JournalHENDERSON, Nev., March 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the publication of a new clinical manuscript demonstrating that nucleosome levels, as measured by Volition's Nu.Q®H3.1 and Nu.Q®H3R8 Citrulline are elevated in people that have experienced a traumatic event and are even higher in those patients that go on to have complications from the trauma. Principal Investigator and Senior Author, Myung S. Park, Professor of Surgery, Associate Medical Director of Research, Trauma Center, Director, Clinical Research Trials Unit, Center for Cl

    3/30/26 8:13:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AKAN
    $CTCX
    $EYPT
    $HLTH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKAN
    $CTCX
    $EYPT
    $HLTH
    SEC Filings

    View All

    SEC Form 6-K filed by Akanda Corp.

    6-K - AKANDA CORP. (0001888014) (Filer)

    4/2/26 5:25:02 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    VolitionRX Limited filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - VOLITIONRX LTD (0000093314) (Filer)

    4/1/26 4:30:19 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-K filed by VolitionRX Limited

    10-K - VOLITIONRX LTD (0000093314) (Filer)

    3/31/26 4:13:53 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AKAN
    $CTCX
    $EYPT
    $HLTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on EyePoint Pharmaceuticals with a new price target

    RBC Capital Mkts initiated coverage of EyePoint Pharmaceuticals with a rating of Outperform and set a new price target of $28.00

    6/17/25 7:49:38 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    H.C. Wainwright initiated coverage on VolitionRx with a new price target

    H.C. Wainwright initiated coverage of VolitionRx with a rating of Buy and set a new price target of $2.50

    4/8/25 8:02:28 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Citigroup initiated coverage on EyePoint Pharmaceuticals with a new price target

    Citigroup initiated coverage of EyePoint Pharmaceuticals with a rating of Buy and set a new price target of $33.00

    1/7/25 7:52:05 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKAN
    $CTCX
    $EYPT
    $HLTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Duker Jay S. bought $19,724 worth of shares (1,500 units at $13.15) (SEC Form 4)

    4 - EyePoint, Inc. (0001314102) (Issuer)

    3/16/26 4:12:55 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    President and CEO Reynolds Cameron John bought $7,000 worth of shares (20,000 units at $0.35), increasing direct ownership by 0.79% to 2,554,847 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    11/17/25 1:12:19 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AKAN
    $CTCX
    $EYPT
    $HLTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Duker Jay S.

    4 - EyePoint, Inc. (0001314102) (Issuer)

    3/24/26 4:05:54 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Rootsaert Rodney Gerard

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    3/19/26 4:30:28 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Forterre Gael

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    3/19/26 4:30:29 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AKAN
    $CTCX
    $EYPT
    $HLTH
    Leadership Updates

    Live Leadership Updates

    View All

    EyePoint Appoints Michael Campbell as Chief Commercial Officer

    – Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma –– Brings established track record of successful product launches and oversight of prominent ophthalmology franchises, including Lucentis® and Xiidra® – WATERTOWN, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Michael Campbell has been appointed Chief Commercial Officer. Mr. Campbell, an experienced commercial leader with a proven track record of successful product launches and oversight of

    2/18/26 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Volition Announces the Appointment of New Distributor for Nu.Q® Discover

    HENDERSON, Nev., Feb. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q® Discover assays in Japan. Dr Jasmine Kway, Chief Executive Officer, Singapore Volition commented: "We are delighted to be working with MBL, a leading provider of clinical research tools in Japan, with a particular focus and track record in autoimmune diseases. "Through our Nu.Q® Discover pillar, we are now serving close to 100 clients worldwide, including many top pharma and diagnostic companies, accelerating disease research and drug developme

    2/10/26 8:07:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

    HENDERSON, Nev., Jan. 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized laboratory providers of its Nu.Q® Vet Cancer test in the U.S. and Asia, further expanding access to its canine cancer early detection tool. Midwest Veterinary Laboratory, a full-service independent reference laboratory in the U.S., will be offering the Nu.Q® Vet Cancer test to its customers across all 50 states from February 2026.Bioguard, a global animal health diagnostics company is now offering the Nu.Q® Vet Cancer Test through it's Animal Health Diagnostic Center, the first certified ISO/IEC 17025 animal diseas

    1/20/26 8:25:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AKAN
    $CTCX
    $EYPT
    $HLTH
    Financials

    Live finance-specific insights

    View All

    VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

    Conference call to discuss financial and operational results scheduled forWednesday, April 1 at 8:30 a.m. U.S. Eastern TimeHENDERSON, Nev., March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the full fiscal year 2025.  Volition management will host a conference call tomorrow, April 1 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said:"We set out over fifteen years ago to help save lives and improve outcomes for millions of

    3/31/26 4:05:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update

    Conference call to take place on Wednesday, April 1 at 8:30 a.m. U.S Eastern TimeHENDERSON, Nev., March 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Wednesday, April 1 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the full fiscal year 2025 and to provide a business update. Details of this event can be found below. Event: VolitionRx Limited Full Fiscal Year 2025 Earnings and Business Update Conference CallDate:  Wednesday, April 1, 2026Time:  8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European TimeU.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (t

    3/25/26 4:12:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026

    WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 4, 2026 to report its fourth quarter and full-year 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/i8pzi8wg. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepoint.bio. A w

    2/25/26 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKAN
    $CTCX
    $EYPT
    $HLTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Carmell Corporation

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    12/6/24 4:16:05 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

    SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

    12/4/24 6:51:18 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care